Novo-Nordisk, DK0062498333

Novo Nordisk stock: CagriSema data bolster obesity pipeline

Published on 11/17/2026 at 17:16 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Novo Nordisk stock faces a fresh obesity-pipeline test after lower-dose CagriSema results. The phase 3 readout adds evidence ahead of a US regulatory decision.

Key points for investors

  • Novo Nordisk reported new phase 3 findings for investigational CagriSema in adults with overweight or obesity.
  • The lower-dose results add clinical evidence to the company's obesity pipeline before a US regulatory decision.
  • CagriSema remains investigational in the United States, where a decision is expected in the fourth quarter of 2026.
Novo-Nordisk, DK0062498333, Illustration mit AI erstellt.

Novo Nordisk announced on Saturday, November 14, primary phase 3 results for investigational CagriSema in the REDEFINE 9 trial. The company said the lower-dose combination of cagrilintide and semaglutide produced estimated average weight loss of 20.7% and 21.0% at week 68, compared with 2.0% for placebo, under the efficacy estimand.

The results were published by Novo Nordisk alongside their presentation at ObesityWeek 2026. REDEFINE 9 evaluated once-weekly CagriSema at 1.7 mg/1.7 mg and 1.0 mg/1.0 mg in 309 adults with obesity or overweight and an obesity-related complication, without diabetes.

Clinical data add pipeline evidence

The company said both doses achieved significantly greater weight loss than placebo. Under the treatment-regimen estimand, which accounts for treatment discontinuation or rescue intervention, estimated weight loss was 19.4% and 18.6% for the two CagriSema doses, compared with 4.6% for placebo.

Gastrointestinal events were the most frequent adverse events and were described as mild to moderate. Permanent treatment discontinuation because of adverse events occurred in 2.9% of participants at the higher lower-dose regimen, 4.9% at the lower regimen and 4.9% with placebo.

Regulatory path remains ahead

CagriSema is not approved in the United States. Novo Nordisk filed a US New Drug Application for the 2.4 mg/2.4 mg dose in December 2025 and expects a decision in the fourth quarter of 2026. The REDEFINE 9 findings are therefore relevant to the broader development program, but they do not themselves constitute a marketing approval.

Novo Nordisk stock traded at 36.84 euros on Lang & Schwarz at 17:06 CET on Tuesday, November 17.

Novo Nordisk company details

  • Company: Novo Nordisk A/S
  • ISIN: DK0062498333
  • Trading venue: Lang & Schwarz
  • Quoted price: 36.84 euros at 17:06 CET on November 17, 2026

European market developments can be followed in Current market reports.

More news and analyses on Novo Nordisk stock.

Disclaimer...
en | DK0062498333 | NOVO-NORDISK | boerse | 70527827 | bgmi